According to Dimitrios Pournaras, MD as reported in the BMJ, "Bariatric surgery (gastric bypass, sleeve gastrectomy, or gastric banding) leads to complete remission in only about one third of patients with type 2 diabetes, and should be viewed as a means for improving glycemic control, not as a cure."...
Using the recently updated American Diabetes Association (ADA) standard, which defined diabetes remission as hemoglobin (Hb) A1c levels below 6% and fasting glucose levels less than 100mg/dL.(5.6 mmol/L ) at least 1 year after bariatric surgery without hypoglycemic medication, the researchers found remission to be substantially lower than had been reported with earlier criteria.
Using data from 1006 patients, 209 of whom had type 2 diabetes at the time of gastric surgery, and a median follow-up of 23 months postsurgery, complete remission rates, using the new ADA standard, were 40.6% after gastric bypass (65/160 patients), 26% after sleeve gastrectomy (5/19 patients), and 7% after gastric banding (2/30 patients). However, the authors explain, "The remission rate for gastric bypass was significantly lower with the new definition than with the previously used definition (40.6 versus 57.5 per cent; P = 0.003)." Remission rates for the other 2 procedures were not significantly different according to the new vs the old criteria.
The data, which were collected prospectively in 2 bariatric surgery centers in the United Kingdom and 1 center in Norway, also showed that on average, patients remained obese after surgery (preoperative body mass index [BMI], 48 kg/m2 vs postoperative BMI, 35 kg/m2). After surgery, oral hypoglycemic medications were still used by 29.4% of gastric bypass patients, 63% of sleeve gastrectomy patients, and 83% of gastric banding patients.
HbA1c levels were significantly lower after surgery in all 3 surgical groups, with mean levels of 6.2% (compared with 8.1% before gastric bypass), 6.8% (compared with 7.5% before sleeve gastrectomy), and 6.3% (compared with 7.7% before gastric banding; P < .001 for each comparison).
The authors note that these findings are important for "establishing realistic expectations among patients, clinicians, and policy-makers" regarding bariatric surgery in the management of type 2 diabetes. They suggest that emphasis should shift to bariatric surgery as an aid in achieving glycemic control, rather than as a tool for achieving remission.
The authors conclude, "The principal benefit of surgery, however, would not be to improve glycemic control per se but rather to reduce microvascular and macrovascular complications associated with diabetes. The findings of this study emphasize the need for intensive follow-up of patients with type II diabetes following bariatric surgery, in order to review pharmacological treatment, monitor for complications of diabetes, and ensure that adequate glycemic control is achieved."
Br J Surg. 2012:88:100-103.
Showing posts with label bariatric surgery. Show all posts
Showing posts with label bariatric surgery. Show all posts
Wednesday, January 25, 2012
Friday, October 14, 2011
Do Bariatric Surgery Patients Fare Better?
A new study in VA patients has found no survival benefit associated with bariatric surgery among older, severely obese people when compared with usual care, at least out to seven years....
Dr. Matthew L. Maciejewski, who presented the findings, stated that doctors "should counsel their patients that there are numerous significant benefits to bariatric surgery -- including the fact that it's the most effective weight-loss treatment, and it improves the control of chronic conditions and quality of life -- but there doesn't appear to be a survival benefit at nearly seven years." It is possible that there will be a survival benefit longer term, he says, and his group is continuing to follow these patients and add in others who have had surgery more recently.
The new findings contrast with those of prior studies, many of which have shown survival benefits with bariatric surgery, but most of which have examined outcomes in younger, primarily white, and female populations, said Maciejewski. But obesity-related mortality is highest in men and minority patients, who have high rates of comorbid diseases, and this is the first study that has looked at long-term survival in such high-risk patients, he points out.
In addition, in this work, statistical analyses were employed, which "represent an advance over prior work. The VA has really rich data sets, and we had body-mass-index [BMI] information on all patients, including the nonsurgical controls," information that provides for more robust results, Maciejewski explains.
Maciejewski et al conducted a retrospective, cohort study of bariatric-surgery programs in VA medical centers, including 850 veterans who underwent Roux-en-Y gastric bypass from January 2000 to December 2006. The population was 74% male, the mean age was 49.5 years, and the mean BMI was 47.4. Race/ethnicity was 78% white, 16% nonwhite, and the remainder "unknown." Mortality for these patients was compared with that of 41,244 nonsurgical controls (mean age 54.7 years, mean BMI 42, 74% male, and 77% white) from the same 12 Veteran Integrated Services Networks.
In unadjusted analyses, bariatric surgery was significantly associated with reduced mortality (hazard ratio 0.64), but in an analysis of 1694 propensity-matched patients, bariatric surgery was no longer significantly associated with reduced mortality in both unadjusted (hazard ratio 0.83) and time-adjusted (HR 0.94) Cox regressions.
Previous studies have mostly identified control patients via the use of a diagnosis code of morbid obesity, says Maciejewski, which "means they were probably not random samples of all patients eligible for surgery, and they were probably a sicker group [than those who underwent bypass], which might overstate the benefits of surgery."
The results highlight the importance of statistical adjustment and careful selection of surgical and nonsurgical cohorts, particularly during evaluation of bariatric surgery according to administrative data. The survival benefits between the bariatric surgery and control group were modest in most previous studies and so may have been attenuated if adjustment for confounders had been possible, they explain.
It will be important to continue to track this cohort to see whether any survival advantages for surgery emerge in the longer term. The fact that no survival advantage has been seen so far is perhaps "not surprising." In the only other trial to have compared bariatric surgery with "high-quality clinical data," the Swedish Obese Subjects (SOS) study, the survival benefit was not observed until a median of 13 years of follow-up.
It will also be necessary to incorporate other patients who have undergone more contemporary laparoscopic gastric banding or gastric-sleeve resections -- procedures that are being performed more and more in the VA system. "It will be important to update the results to account for those procedures," Maciejewski observes.
But, in the meantime, even though bariatric surgery is not associated with reduced mortality, many patients may still choose to undergo such procedures, "given the strong evidence for significant reductions in body weight and comorbidities and improved quality of life," the researchers conclude.
Dr. Matthew L. Maciejewski, who presented the findings, stated that doctors "should counsel their patients that there are numerous significant benefits to bariatric surgery -- including the fact that it's the most effective weight-loss treatment, and it improves the control of chronic conditions and quality of life -- but there doesn't appear to be a survival benefit at nearly seven years." It is possible that there will be a survival benefit longer term, he says, and his group is continuing to follow these patients and add in others who have had surgery more recently.
The new findings contrast with those of prior studies, many of which have shown survival benefits with bariatric surgery, but most of which have examined outcomes in younger, primarily white, and female populations, said Maciejewski. But obesity-related mortality is highest in men and minority patients, who have high rates of comorbid diseases, and this is the first study that has looked at long-term survival in such high-risk patients, he points out.
In addition, in this work, statistical analyses were employed, which "represent an advance over prior work. The VA has really rich data sets, and we had body-mass-index [BMI] information on all patients, including the nonsurgical controls," information that provides for more robust results, Maciejewski explains.
Maciejewski et al conducted a retrospective, cohort study of bariatric-surgery programs in VA medical centers, including 850 veterans who underwent Roux-en-Y gastric bypass from January 2000 to December 2006. The population was 74% male, the mean age was 49.5 years, and the mean BMI was 47.4. Race/ethnicity was 78% white, 16% nonwhite, and the remainder "unknown." Mortality for these patients was compared with that of 41,244 nonsurgical controls (mean age 54.7 years, mean BMI 42, 74% male, and 77% white) from the same 12 Veteran Integrated Services Networks.
In unadjusted analyses, bariatric surgery was significantly associated with reduced mortality (hazard ratio 0.64), but in an analysis of 1694 propensity-matched patients, bariatric surgery was no longer significantly associated with reduced mortality in both unadjusted (hazard ratio 0.83) and time-adjusted (HR 0.94) Cox regressions.
Previous studies have mostly identified control patients via the use of a diagnosis code of morbid obesity, says Maciejewski, which "means they were probably not random samples of all patients eligible for surgery, and they were probably a sicker group [than those who underwent bypass], which might overstate the benefits of surgery."
The results highlight the importance of statistical adjustment and careful selection of surgical and nonsurgical cohorts, particularly during evaluation of bariatric surgery according to administrative data. The survival benefits between the bariatric surgery and control group were modest in most previous studies and so may have been attenuated if adjustment for confounders had been possible, they explain.
It will be important to continue to track this cohort to see whether any survival advantages for surgery emerge in the longer term. The fact that no survival advantage has been seen so far is perhaps "not surprising." In the only other trial to have compared bariatric surgery with "high-quality clinical data," the Swedish Obese Subjects (SOS) study, the survival benefit was not observed until a median of 13 years of follow-up.
It will also be necessary to incorporate other patients who have undergone more contemporary laparoscopic gastric banding or gastric-sleeve resections -- procedures that are being performed more and more in the VA system. "It will be important to update the results to account for those procedures," Maciejewski observes.
But, in the meantime, even though bariatric surgery is not associated with reduced mortality, many patients may still choose to undergo such procedures, "given the strong evidence for significant reductions in body weight and comorbidities and improved quality of life," the researchers conclude.
Subscribe to:
Posts (Atom)
